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Abstract
Variation in steroid hormone levels has wide implications for health and disease. The
genes encoding the proteins involved in steroid disposition represent key determinants of
interindividual variation in steroid levels and ultimately, their effects. Beginning with meta-
bolomic data from genome-wide association studies (GWAS), we observed that genetic
variants in the orphan transporter, SLC22A24 were significantly associated with levels
of androsterone glucuronide and etiocholanolone glucuronide (sentinel SNPs p-value
<1x10-30). In cells over-expressing human or various mammalian orthologs of SLC22A24,
we showed that steroid conjugates and bile acids were substrates of the transporter. Phy-
logenetic, genomic, and transcriptomic analyses suggested that SLC22A24 has a special-
ized role in the kidney and appears to function in the reabsorption of organic anions, and
in particular, anionic steroids. Phenome-wide analysis showed that functional variants
of SLC22A24 are associated with human disease such as cardiovascular diseases and
acne, which have been linked to dysregulated steroid metabolism. Collectively, these
functional genomic studies reveal a previously uncharacterized protein involved in steroid
homeostasis, opening up new possibilities for SLC22A24 as a pharmacological target for
regulating steroid levels.
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Author summary
Steroid hormones, ranging from sex steroids such as testosterone to glucocorticoids play
key roles in human health and disease. Accordingly, the identification of the genes and
proteins involved in their synthesis, disposition and elimination has been the subject of
numerous genetic studies. We have been intrigued by recent studies demonstrating that
genetic variants in or near a gene encoding SLC22A24 are strongly associated with steroid
levels. SLC22A24 is an orphan transporter with no known ligands and no known biologi-
cal functions. In this study, we use cellular and computational methods to show that
SLC22A24 transports steroid conjugates, bile acids, and other dicarboxylic acids. Based
on the direction of association of a common stop codon in SLC22A24 with lower levels of
steroids, our studies suggest that the transporter functions to reabsorb steroid conjugates
in the kidney, a surprising finding, given that conjugation pathways generally function to
create polar molecules that are readily eliminated by the kidney. The absence of the trans-
porter gene in many species and its presence in higher order primates both suggest that
SLC22A24 plays a specialized role in steroid homeostasis. Overall, our studies indicate
that SLC22A24 functions in the reabsorption of conjugated steroids in the kidney.
Introduction
Steroid hormones represent major signaling molecules and have been the subject of numerous
investigations[1]. Precise regulation of steroid levels is important for human health and dis-
ease, which has stimulated many studies focused on the identification and characterization of
the genes, proteins, and pathways involved in steroid metabolism and disposition. In addition,
genome-wide association studies (GWAS) have been performed to identify the polymor-
phisms that associate with interindividual variation in the levels of steroids, and to discover
additional genes that are involved in steroid disposition. In general, multiple GWAS have led
to the identification of genes already known to be involved in steroid metabolism, binding and
regulation [2–7]. However, one locus, SLC22A24, has puzzled researchers because it has no
known role in steroid homeostasis [6, 8, 9]. SLC22A24 encodes an orphan solute carrier (SLC)
transporter which has no currently known ligands.
The human solute carrier (SLC) transporter superfamily includes approximately 400 pro-
teins grouped into 52 families [10–13]. SLC22A24, an orphan transporter, belongs to the
SLC22 family, which transports organic ions [14]. In the human genome, the SLC22 family
includes 22 members and represents the third largest in the SLC transporterome, behind
SLC25 and SLC35 families. The first human member of this family was cloned and character-
ized in 1997 [15, 16], and since then, members of the family were shown to play critical phar-
macological roles in mediating the hepatic and renal elimination of a variety of endogenous
compounds and drugs (e.g., SLC22A1 encoding organic cation transporter 1 (OCT1),
SLC22A2 encoding OCT2, SLC22A6 encoding organic anion transporter 1 (OAT1), and
SLC22A8 encoding OAT3)[17, 18]. Because of their important pharmacologic role, many
members of the SLC22 family are recognized as important determinants of drug disposition
and mediators of drug-drug interactions [17], and are frequently studied during drug develop-
ment [12].
In spite of the increasing recognition as playing key roles in drug response and toxicity,
and indeed in human physiology and pathophysiology, the SLC22 family still contains a large
cluster of orphan transporters, including SLC22A10, SLC22A14, SLC22A15, SLC22A17,
SLC22A18, SLC22A23, SLC22A24, SLC22A25, and SLC22A31 [19, 20]. In fact, close to 75
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members of the human SLC superfamily remain classified as orphan transporters, i.e., they
have no assigned ligands [10, 11, 21]. A number of factors appear to contribute to this paradox
including a non-unified nomenclature and technical challenges involved in working with
membrane proteins[11].
SLCs that have been characterized to date function in the transmembrane flux of solutes,
which include inorganic ions, such as heavy metals, as well as organic compounds, such as
neurotransmitters and amino acids. Therefore, the key step in understanding the physiological
role of these proteins is identifying their endogenous substrates.
Over the years, various functional and molecular approaches have been employed to iden-
tify the endogenous ligands of SLC transporters. One robust approach for the identification of
substrates has been the use of genome-wide association studies (GWAS) to identify single
nucleotide polymorphisms (SNPs) in SLCs that associate with circulating levels of various
metabolites. For example, the discovery of GLUT9 (encoded by SLC2A9) as a uric acid trans-
porter stemmed from a GWAS focused on the identification of genetic variants associated
with hyperuricemia and gout [22, 23]. Further, the characterization of SLC16A9 as a carnitine
efflux transporter was motivated by a GWAS with metabolomics [24]. Also, tetradecanedioic
acid and hexadecanedioic acid were discovered to be naturally occurring substrates of
OATP1B1 (encoded by SLCO1B1) in a GWAS aimed at identifying metabolomic biomarkers
for the transporter [25, 26].
In this study, we used a combination of computational and experimental approaches to
uncover endogenous ligands and substrates of SLC22A24. These approaches included radiola-
beled substrate and inhibition screens, metabolomic profiling of cells over-expressing
SLC22A24, and sequence and structure-based analyses. To provide further support for the
endogenous role of the human SLC22A24, we profiled its expression levels in various tissues
and cell types. Phylogenetic analysis revealed that the transporter has orthologs in primates
and a few other mammalian species, suggesting a specialized role of the transporter. Our work
also implicates the transporter in the disposition of drugs and drug metabolites with a steroid
scaffold. To our knowledge, this is the first study to identify endogenous and pharmacological
substrates of SLC22A24. Further studies are warranted to understand the complete physiologi-
cal and pharmacological roles of the transporter in human and primate biology.
Results
GWAS reveal strong associations of SLC22A24 polymorphisms with steroid
metabolite levels
Three independent GWAS reveal strong associations of SNPs in SLC22A24 with steroid levels.
In particular, the metabolites that reached genome-wide significance included progesterone
(p<10−11)[6], androsterone glucuronide (sentinel SNP p<10−50)[8, 9], and etiocholanolone
glucuronide (sentinel SNP p<10−30)[8]. A locus zoom plot shows the significance pattern of
SNPs in and around SLC22A24 for the association with androsterone glucuronide (Fig 1A),
etiocholanolone glucuronide (Fig 1B) and pregnanediol-3-glucuronide (Fig 1C). The SNPs
in the vicinity of SLC22A24 have the most significant associations with androsterone glucuro-
nide and etiocholanolone glucuronide in GWAS [8, 9]. The top SNPs for progesterone
(rs112295236) and the sentinel SNPs for androsterone glucuronide and etiocholanolone glucu-
ronide (rs78176967, rs151042642)[6, 8, 9] are in the region between SLC22A24 and SLC22A8.
These SNPs are in strong linkage disequilibrium (LD), r2>0.8, to SNPs within SLC22A24
(Fig 1A and 1B). Interestingly, a nonsense variant in SLC22A24 (rs11231341, Tyr501Ter,
c.1503T>G), is strongly associated with the levels of androsterone glucuronide and etiochola-
nolone glucuronide (p<5x10-8) (Fig 1A and 1B). Using LDLink[27], we identified the SNPs in
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Fig 1. Genetic associations of variants in the SLC22A24 locus with steroid glucuronide levels. LocusZoom plot showing association results of top
variants in the SLC22A24 locus with (A) androsterone glucuronide (X-22379), (B) etiocholanolone glucuronide and (C) pregnanediol-3 glucuronide. The
LD estimates are color coded as a heatmap from dark blue (0<r2<0.2) to red (0.8<r2<1.0). Recombination rate are indicated by the solid blue lines
(recombination rate in cM/Mb from HapMap). The bottom panel shows the genes and their orientation. The associations were plotted using available data
from Long T. et al. (http://www.hli-opendata.com/Metabolome/, S1 Table). Underlying data are also provided in S1 Data. (D) The linkage disequilibrium
as calculated by D prime (D’) and correlations (r2) between the top SNPs rs781769767 and rs151042642 with missense and nonsense variants in
SLC22A24, SLC22A25 and SLC22A10. (E) Genetic association of SLC22A24 p.Tyr501Ter with normalized residuals of androsterone glucuronide and
etiocholanolone glucuronide in the ARIC study (N = 1375 Caucasians). The major allele of rs11231341 coding for p.Tyr501Ter is significantly associated
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linkage with rs78176967 and rs151042642, and found that among the missense, nonsense,
or splice donor variants in SLC22A24 (rs11231341, rs7945121, rs1939749), SLC22A25
(rs6591771) and SLC22A10 (rs1790218, rs1201559), the SLC22A24 p.Tyr501Ter (rs11231341)
has the strongest correlation to the top SNPs associated with the steroid glucuronides, with r2
= 0.22, D’ = 1.0 (Fig 1D). In addition to the published data, we used data from the Atheroscle-
rosis Risk in Communities Study (ARIC) to confirm the direction of the association of the
nonsense variant, SLC22A24 p.Tyr501Ter, with plasma levels of the two metabolites. In partic-
ular, this independent cohort consists of 1,375 Caucasians and 573 African Americans with
available genotype data and steroid metabolite levels. Primary analysis showed that the major
allele (G-allele), encoding the nonsense variant SLC22A24 p.Tyr501Ter, is associated with
lower plasma levels of the two steroid glucuronide conjugates, androsterone glucuronide
and etiocholanolone glucuronide (Fig 1E, Table 1). Further, association analysis in ARIC
study also confirmed weaker associations of other missense variants or nonsense variants in
SLC22A25 and SLC22A10 (S2 Table).
We were puzzled by the observation that the sentinel SNPs, rs78176967 and rs151042642,
exhibited stronger associations with steroid levels (p-values range from 1x10-55 to 9x10-11)
than the nonsense SNP, rs11231341 (encoding p.Tyr501Ter, p-values range from 0.0014–
1x10-13) (Table 2). As the sentinel SNPs, rs78176967 and rs151042642, are intergenic variants
with no known or predicted cis-regulatory effects, we suspected that they may tag true causal
variants that are linked to them in addition to rs11231341. Searching for publicly available
eQTL, we noted that the splice donor variant in SLC22A24, rs1939749, is the top SNP for asso-
ciations with SLC22A24 transcript levels in kidney eQTL databases[28–30] (S1 Fig). In particu-
lar, rs1939749 resides at the 3’ junction of exon 1 and could affect splicing between exons 1
and 2. Incorrect splicing at the 3’ junction of exon 1, i.e., with the minor allele variant,
with lower serum levels of androsterone glucuronide and etiocholanolone glucuronide (see Table 1). Underlying data are provided in S1 Data. (F)
Haplotype frequencies of the haplotypes observed for the list of query variants in European population from Phase 3 of the 1000 Genomes Project. This
plot is created using LDhap https://ldlink.nci.nih.gov/?tab=ldhap[27].
https://doi.org/10.1371/journal.pgen.1008208.g001
Table 1. Association of SLC22A24 p.Tyr501Ter (rs11231341, c.1503T>G) with two steroid conjugates in three cohorts. Association of SLC22A24 p.Tyr501Ter
(rs11231341, c.1503T>G) with steroid glucuronide levels. Major G-allele (coding for SLC22A24 p.Tyr501Ter) is associated with lower steroid glucuronide levels. The data
from ARIC cohort are available through the established database of Genotypes and Phenotypes (dbGaP) application procedure for the ARIC study (dbGaP Study Acces-
sion: phs000280.v5.p1).
SNP
(rsID)
A1 A2 Effect
Allele
Effect Allele
Freq
N Beta SE P-value Cohort Metabolite Source
rs11231341 T G G 0.83 1375 -0.39 0.051 1.73E-
13
ARIC (European) Androsterone glucuronide
(X-22379)
This study
rs11231341 T G G 0.62 573 -0.20 0.064 0.0014 ARIC (African
American)
This study
rs11231341 T G G 0.79 564 -0.30 0.067 5.43E-
06
Middle Eastern Using data computed from
Yousri et al.[9]
rs11231341 T G G 0.81 1895 -0.36 0.053 1.06E-
13
European (Long T) Reference[8]
rs11231341 T G G 0.83 1375 -0.29 0.051 3.14E-
08
ARIC (European) Etiocholanolone glucuronide This study
rs11231341 T G G 0.62 573 -0.21 0.064 0.0012 ARIC (African
American)
This study
rs11231341 T G G 0.79 554 -0.34 0.072 3.41E-
06
Middle Eastern Using data computed from
Yousri et al.[9]
rs11231341 T G G 0.81 1903 -0.26 0.053 6.04E-
09
European (Long T) Reference[8]
https://doi.org/10.1371/journal.pgen.1008208.t001
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would result in a premature stop codon (S1 Fig). We hypothesized that rs1939749 drives the
SLC22A24 expression levels and thus the minor allele results in lower transcript levels (S1 Fig).
Interestingly, the minor alleles (A-alleles) of the sentinel SNPs (rs78176967 and rs151042642)
are in complete linkage disequilibrium (D’ = 1) with the major allele (G-allele) of rs1939749
and the minor allele (T-allele) of rs11231341 encoding Tyr501 (Fig 1F). The resultant haplo-
type, rs78176967:rs151042642:rs11231341:rs1939749 = A:A:T:G, which is present at ~5% hap-
lotype frequency, is expected to retain function as there is no stop codon present at position
501 (T-allele) and no defective splicing (G-allele). The weaker p-value of the allele encoding
Tyr501, rs11231341, is due to the fact that it may occur in two distinct haplotypes, one that is
a loss of function due to the allele that is predicted to disrupt splicing (rs1939749), and one
that retains function (no splicing defect) (Fig 1F). Overall, these results led to further studies
designed to explore the functional role of SLC22A24 as a transporter of steroids and steroid
conjugates.
Metabolomic studies and comparative structure modeling reveal
SLC22A24 as an organic anion transporter
Metabolomic study. Large-scale metabolomic studies have been previously used in our
laboratory and others to identify transporter substrates in an unbiased manner [31–33]. The
technological advances of state-of-the-art metabolomic methods have allowed for increased
sensitivity and accuracy in the quantification of small molecules, elevating the number of
detectable endogenous metabolites achieving a Tier 1 standard for identification to over 700
[34] (S3 Table). In this study, we transiently transfected HEK293 Flp-In cells with either empty
vector (EV) or SLC22A24. SLC22A1 was transiently transfected as a positive control (S3
Table). We then incubated the cells with fetal bovine serum. Results in S3 Table show that
many known metabolite substrates of SLC22A1 were significantly different between SLC22A1
and EV transfected cells, for example known substrates thiamine and acylcarnitines [31, 35]. A
total of 50 metabolites reached the threshold of significance for difference in abundance
between EV cells and SLC22A24 expressing cells (Fig 2A and 2B). Among the top 10 metabo-
lites, four were bile acids (taurocholic acid, taurodeoxycholic acid, glycocholic acid and tauro-
chenodeoxycholic acid), which have a steroid backbone, and two were dicarboxylic acids
(3-hydroxy-3-methylglutarate and succinic acid) (Fig 2). Steroids and steroid conjugates were
not above the threshold of detection in the cellular metabolomic analysis (S3 Table), poten-
tially because of intrinsically low levels of endogenous steroids in the cell culture media con-
taining fetal bovine serum [36]. Although most of the metabolites were present in greater
abundance in the SLC22A24 expressing cells compared with EV cells, a few were present at
lower abundance. Other anionic metabolites among the top 50 had monocarboxylic acid,
phosphate, or sulfate moieties (S3 Table).
Table 2. Association of sentinel SNPs with two steroid conjugates in three cohorts. Association of sentinel SNPs with steroid glucuronide levels in two published stud-
ies and in the ARIC cohort. According to 1000 Genome Project, European population, these SNPs (rs78176967, rs61285056 and rs151042642) are in strong LD with one
another (D’ = 1, r2>0.95). The A1 and A2 alleles are on the minus strand. The primary data are available through the established dbGaP application procedure for the
ARIC study (dbGaP Study Accession: phs000280.v5.p1).
SNP (rsID) A1 A2 Effect Allele Effect Allele Freq N Beta SE P-value Cohort Metabolite Source
rs78176967 C A A 0.063 1895 1.14 0.08 1.17E-55 European (Long T) Androsterone glucuronide (X-22379) Reference[8]
rs61285056 C A A 0.058 564 0.77 0.12 9.11E-11 Middle Eastern Reference[9]
rs61285056 C A A 0.064 1456 1.17 0.077 7.03E-53 ARIC (European) This study
rs151042642 G A A 0.063 1903 0.90 0.09 9.13E-38 European (Long T) Etiocholanolone glucuronide Reference[8]
rs61285056 C A A 0.061 1456 0.95 0.077 2.94E-35 ARIC (European) This study
https://doi.org/10.1371/journal.pgen.1008208.t002
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Fig 2. Metabolomic study and comparative structure models support the role of SLC22A24 as an anion
transporter. (A) Cellular metabolite levels are significantly different between HEK293 Flp-In cells transiently
transfected with empty vector (EV) or SLC22A24 for seven bile acids and six dicarboxylic acids among the top 50
metabolites. Underlying data are provided in S1 Data. (B) Chemical structures of the seven bile acids and six
dicarboxylic acids. (C) Surface representations of the calculated electrostatic potential (-5 to 5 kT e-1) of the human
SLC22A1, a characterized cationic transporter, the human SLC22A6, a characterized anionic transporter, and the
human SLC22A24. The cross-section allows for visual inspection of the predicted binding pocket.
https://doi.org/10.1371/journal.pgen.1008208.g002
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Comparative structure modeling. Due to the lack of available crystal structures for most
SLC transporters, we modeled the human SLC22 members using the crystal structure of the
human GLUT3 (SLC2A3) as a template. We hypothesized that despite the low sequence iden-
tity, the alignment would lead to an accurate assignment of residues along the helices, thus
allowing an analysis of the electrostatic potential within the orthosteric site. As a control, we
first modeled SLC22A1, a well-characterized organic cation transporter, and SLC22A6, an
organic anion transporter (Fig 2C). A visual inspection of the electrostatic potential within the
pocket was in agreement with the charges of known substrates. That is, the dominant charge
within the SLC22A1 pocket was negative and within the SLC22A6 pocket was positive, consis-
tent with binding and translocation of cationic and anionic substrates, respectively. The exten-
sion of the same methodology to SLC22A24 showed the pocket to carry an overall positive
charge, implying an affinity for anionic compounds, and consistent with our metabolomic
findings (Fig 2).
A diverse set of in vitro transporter assays supports the role of SLC22A24
as an organic anion transporter
We performed an uptake screen of 21 radiolabeled canonical substrates of various SLC22 fam-
ily members, spanning cations, anions, and zwitterions. The experiments confirmed that
SLC22A24 is a transporter of select organic anions (S4 Table).
Cells transiently transfected with SLC22A24 accumulated steroid anionic compounds,
including [3H]-taurocholic acid (TA) (10–20 fold over empty vector control), [3H]-glycocholic
acid (GA) (10–20 fold), [3H]-estrone sulfate (ES) (5–10 fold), [3H]-estradiol-17β-glucuronide
(EG) (3–5 fold), and [3H]-androstanediol glucuronide (AG) (5–15 fold) (Fig 3A). The uptakes
of [3H]-estrone sulfate, [3H]-estradiol-17β-D-glucuronide, [3H]-androstanediol glucuronide,
[3H]-taurocholic acid and [3H]-glycocholic acid were time dependent, reaching plateaus at
approximately 5 min (S2 Fig). Kinetic parameters were evaluated at 1 min, except the uptake
rate of taurocholic acid, which was evaluated at 2 min. The uptake kinetics of [3H]-estrone sul-
fate, [3H]-estradiol-17β-D-glucuronide, [3H]-taurocholic acid, and [3H]-glycocholic acid
exhibited saturable characteristics at higher concentrations, with Km values (mean ± SD) of
8.6 ± 0.3 μM, 17.5 ± 0.2 μM, 10.5 ± 1.1 μM, and 33.4 ± 2.5 μM, respectively (Fig 3B, S5 Table).
Similar values were observed for SLC22A8 (S5 Table). The kinetic parameters of androstane-
diol-3-glucuronide could not be determined accurately in SLC22A24 expressing cells due to a
solubility limit of 300 μM (S3 Fig). Using the plateau at 300 μM as an approximation, the Km
of androstanediol glucuronide for SLC22A24 was estimated to be 741 ± 253 μM, which is
higher than for SLC22A8.
Next, we characterized the uptake of monocarboxylic and dicarboxylic acid derivatives,
which are known substrates of other anion transporters, including several prescription drugs.
Among the compounds that were identified as substrates of SLC22A24, two were dicarboxylic
acids (i.e. succinic acid and 6-carboxyfluorescein, 6-CF) and two were monocarboxylic acids
(i.e. 4’,5’-dibromofluorescein, DBF, and 2’7’-dichlorofluorescein, DCF) (Fig 3C). However,
other anion substrates of SLC22A6, SLC22A7, or SLC22A8, were determined not to be sub-
strates of SLC22A24. Those include para-aminohippuric acid (PAH), uric acid, orotic acid,
alpha-ketoglutaric acid and tetradecanedioic acid (S4 Table). The prescription drug, metho-
trexate, and the mycotoxin, ochratoxin A, showed significant uptake by SLC22A24 expressing
over EV cells (Fig 3D), whereas tenofovir and adefovir, which have phosphate moieties, were
not substrates of the transporter (S4 Table). Further, none of the tested cationic and zwitter-
ionic substrates of SLC22A1-SLC22A5 showed significant (>1.5 fold) accumulation in
SLC22A24 expressing cells compared to EV cells (S4 Table).
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Fig 3. Uptake and inhibition studies of various anions in HEK293 Flp-In cells stably expressing SLC22A24. (A) Uptake of steroid sulfate or
glucuronide (ES, DHEAS, AG, EG) conjugates and bile acids (GA, TA). Uptake of these anions was significantly different between EV and SLC22A24
transfected cells. Uptake was significantly reduced in the presence of excess unlabeled estrone sulfate. Figure shows a representative plot from one
experiment (mean ± S.D. from three replicate wells). The experiments were repeated at least one time and showed similar results. (B) Kinetics of uptake
of four anions for SLC22A24. The uptake rate was evaluated at 1 minute, except for taurocholic acid, which was evaluated at 2 min. Each point
represents the uptake (mean ± S.D.) in cells stably expressing SLC22A24, normalized to the empty vector control. The data were fit to a Michaelis–
Menten equation. The figure shows a representative plot from one experiment. The mean and S.D. of the kinetic parameters from two experiments are
shown in S5 Table. The time-dependent uptakes of selected anions are shown in S2 Fig. (C, D) Uptake of anions with carboxylic acid and dicarboxylic
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Collectively, the data indicate that SLC22A24 transports various organic anions, including
steroid compounds with anionic moieties (sulfates, carboxylic acids, glucuronides) and non-
steroid compounds with dicarboxylic acid moieties.
SLC22A24 transport is chloride sensitive and transtimulated by glutaric
acid
We examined the underlying transport mechanism of SLC22A24 in order to determine
whether it relies on facilitative diffusion or on secondary active transport of ions. Uptake of
[3H]-estrone sulfate was not affected by pH between 5.5 to 8.5 and was not dependent on the
presence of Na+ ions (S4 Fig). However, uptake of [3H]-estrone sulfate, as well as that of other
steroid conjugates, was significantly affected by the presence of Cl- ions. Cl-free buffer nearly
doubled the uptake of all tested compounds (Fig 3E). In addition, we tested trans-stimulation
of SLC22A24-mediated uptake by preloading the cells with succinic acid, alpha-ketoglutaric
acid, and glutaric acid, which are known to trans-stimulate other organic anion transporters
[37–39]. Among the three, only glutaric acid significantly increased the uptake of [3H]-estrone
sulfate, [3H]-estradiol glucuronide, [3H]-androstanediol glucuronide, and [3H]-taurocholic
acid (Fig 3F).
SLC22A24 is inhibited by anionic compounds from different chemical
classes
The primary goal of the inhibition studies was to confirm that solutes identified in the metabo-
lomic studies were ligands of SLC22A24 and to identify additional ligands of the transporter.
The secondary goal was to determine whether known inhibitors of other organic anion trans-
porters in the SLC22 family were inhibitors of SLC22A24. A total of 85 compounds were
selected for inhibition studies of SLC22A24-mediated [3H]-taurocholic acid uptake (S6 Table,
Fig 4A). These included: (i) 4 steroid metabolites identified in GWAS at p<1x10-6; (ii) 20
known inhibitors or substrates of other organic anion transporters; (iii) 17 steroids or bile
acids which are used clinically; (iv) 8 dicarboxylic acid metabolites identified in our metabolo-
mic study; and (v) 20 steroid conjugates.
At 100 μM, 43 of the 86 test-compounds inhibited the SLC22A24-mediated [3H]-taurocho-
lic acid uptake by>50%. All 16 bile acids, 5 of the 15 unconjugated steroids, 15 of the 20
steroid conjugates, and 12 of the 22 other anionic non-steroidal compounds inhibited tauro-
cholic acid uptake by>50% (Fig 4A, S6 Table). Many sulfate conjugates including steroid sul-
fates inhibited taurocholic acid uptake. Some non-steroidal compounds known to inhibit
organic anion transporters also inhibited SLC22A24-mediated taurocholic acid uptake
potently (e.g. losartan, rosiglitazone, lesinurad, benzbromarone) or partially (e.g. probenecid,
bumetanide, ketoprofen). Three steroid metabolites identified in the GWAS, progesterone,
androsterone glucuronide, and etiocholanolone glucuronide inhibited taurocholic acid uptake
>50%. Consistent with these results, SNPs in SLC22A24 were associated with progesterone,
acid groups. Uptake of these anions was significantly different between cells stably expressing SLC22A24 and the empty vector control cells. Uptake
was reduced significantly in the presence of excess unlabeled estrone sulfate. Figure shows a representative plot from one experiment (mean ± S.D.
from three replicate wells). The experiments were repeated at least one time and showed similar results. (E) Uptake of four anions in HEK293 Flp-In
cells stably expressing SLC22A24 with chloride-containing and chloride-free buffer. Each bar represents uptake (mean ± S.D. from three replicate
wells) in the SLC22A24-transfected cells normalized to the empty vector control. The experiments were repeated at least one time and showed similar
results. (F) Trans-stimulation of SLC22A24–mediated ES, EG, AG and TA uptake. The uptake of ES, EG, AG and TA were trans-stimulated by
separately preloading the cells with 2 mM of succinic acid, alpha-ketoglutrate acid, or glutaric acid for 2 h. After preloading, the uptake of the anions
was measured after 10 min. Data are means ± S.D. The experiments were repeated one time, in triplicate, and show similar results. All experiments
were normalized by setting the uptake of SLC22A24-expressing cells without preloading to 100%. Underlying data are provided in S1 Data.
https://doi.org/10.1371/journal.pgen.1008208.g003
Function of the orphan solute carrier SLC22A24 in steroid transport
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1008208 September 25, 2019 10 / 38
Fig 4. Inhibition studies of various anions in HEK293 Flp-In cells stably expressing SLC22A24. (A) Inhibition of
[3H]-taurocholic acid uptake (with 1 μM unlabeled taurocholic acid) in cells stably expressing SLC22A24 by various
bile acids, steroids, steroid conjugates, dicarboxylic acids, non-steroidal drugs, and other substances. All compounds
were screened at 100 μM, and for some compounds, also at 1 mM. Uptake of [3H]-taurocholic acid was stopped after
10 min. Values represent the mean ± S.E.M. (from at least one experiment with three replicate wells each time).
�Compounds that are statistically significant in the metabolomic analysis. #Steroidal compounds that are statistically
significant in the genome-wide association studies. (B) Inhibition plots for SLC22A24-mediated taurocholic acid
uptake in HEK293 Flp-In cells stably expressing SLC22A24. Cells were incubated with HBSS buffer containing
taurocholic acid (1 μM) for 10 min with or without various concentrations of the compounds. Values are presented as
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androsterone glucuronide and etiocholanolone glucuronide at genome-wide significance levels
(p<5x10-8), whereas associations were weaker for pregnanediol-3-glucuronide (p = 2x10-7),
which was a weaker inhibitor of SLC22A24-mediated taurocholic acid uptake (Fig 4A) [8]. At
a high concentration (1 mM), five of the nine dicarboxylic acids inhibited taurocholic acid
uptake by approximately 50% (Fig 4A). However, UDP-glucuronate and N-acetylasparagine
did not inhibit taurocholic acid uptake even at 1 mM.
Ten compounds were selected for further IC50 studies (Table 3). We specifically focused on
the steroids and steroid conjugates reported in GWAS and the steroid conjugates with the
strongest inhibition in the initial screen. Two bile acids, chenodeoxycholic acid and urso-
deoxycholic acid, were selected because they are used clinically to treat gallstone and related
cholestatic liver disease [40, 41]. Two non-steroidal drugs, rosiglitazone and lesinurad, were
selected because of their strong inhibition in the initial screen. Pregnenolone sulfate, cheno-
deoxycholic acid, and rosiglitazone exhibited potent IC50 values (IC50 < 5 μM) (Fig 4B).
Progesterone, ursodeoxycholic acid, and lesinurad were also inhibitors with IC50 < 20 μM.
Finally, the three steroid glucuronide conjugates, androsterone glucuronide, etiocholanolone
glucuronide, and androstanediol-3-glucuronide, achieved IC50 values for inhibition of
SLC22A24-mediated taurocholic acid uptake of 45 ± 29 μM, 57 ± 36 μM and 21 ± 11 μM,
respectively (Table 3). The IC50 values of androsterone glucuronide and etiocholanolone glu-
curonide are relatively similar to the reported concentrations of these metabolites in the urine
(ranges from 1–33 μM for androsterone glucuronide and 0.9–20.4 μM for etiocholanolone glu-
curonide) [42, 43].
SLC22A24 orthologs exhibit substrate selectivity differences
Phylogenetic analysis. First, we determined the relationships between the human
SLC22A24 with other human, mouse, and rat SLC22 family members with known substrates
(Fig 5A). In the phylogenetic analysis we also included genes within the locus between
mean ± S.D. of taurocholic acid uptake from three replicate wells determined in a single experiment. The experiments
were repeated once and similar results were obtained. Representative curves of the SLC22A24-mediated taurocholic
acid uptake inhibition by steroid conjugates (progesterone sulfate, etiocholanolone glucuronide), bile acid, and drugs
(chenodeoxycholic acid, lesinurad, rosiglitazone). Underlying data are provided in S1 Data. See Table 3 for the IC50
values.
https://doi.org/10.1371/journal.pgen.1008208.g004
Table 3. Inhibition potencies of steroid, steroid conjugates, bile acids and drugs for SLC22A24-mediated tauro-
cholic acid uptake. The experiments were repeated at least once to obtain IC50 mean ± SD (the inhibition concentra-
tion at 50% taurocholic acid uptake).
Compound Class IC50 [μM ± SD]
Progesterone Steroid 7.4 ± 3.0
Pregnenolone sulfate� Steroid conjugate 1.4 ± 0.1
5α-Androstan-3α-ol-17-one glucosiduronate (androsterone glucuronide) 45 ± 29
5β-Androstan-3α-ol-17-one glucosiduronate (etiocholanolone glucuronide)� 57 ± 36
5α-Androstan-3α,17β-diol 3-glucuroside (androstanediol glucuronide) 21 ± 11
Pregnanediol-3-glucuronide > 200
Chenodeoxycholic acid� Bile acid 2.6 ± 1.0
Ursodeoxycholic acid 7.6 ± 1.2
Lesinurad� Drug 13 ± 6.1
Rosiglitazone� 3.3 ± 1.4
�Representative IC50 curves for these compounds are shown in Fig 4B.
https://doi.org/10.1371/journal.pgen.1008208.t003
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Fig 5. Phylogenetic tree analyses and uptake of anions by species orthologs of SLC22A24. (A) Sequence comparison of human, mouse, and rat
protein sequences for all characterized SLC22 family members. Proteins are colored by organism. Red arrow points to the human SLC22A24. (B)
Sequence comparison of characterized human anion transporters and select mammalian orthologs. Red arrow points to the human SLC22A24. (C)
Fold uptake of four substrates by species orthologs of SLC22A24 and rat Slc22a9/Slc22a24 over empty vector control. Uptake of estrone sulfate,
androstanediol glucuronide, estradiol glucuronide, and taurocholic acid was performed in HEK293 Flp-In cells transiently expressing SLC22A24 from
human, mouse lemur, rabbit and horse or Slc22a9/a24 from rat. Uptakes were performed for 10 minutes. The number above the bar is fold uptake
over EV cells from one experiment (mean ± S.D., from four replicate wells). The experiments were repeated one time and similar results were
obtained. Underlying data are provided in S1 Data.
https://doi.org/10.1371/journal.pgen.1008208.g005
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SLC22A8 and SLC22A9, known as the “unknown substrate transporters (USTs)” [44]. Nota-
bly, the number of genes annotated as USTs in mouse and rat is different from human. Mouse
USTs include Slc22a26, a27, a28, a29, a30, a9/a19. Rat USTs include Slc22a9/a24, a9/a25,
Ust4r, Ust5r. This analysis showed that human SLC22A24 lacks close human paralogs and
rodent orthologs, unlike some well-characterized SLC22 family members such as SLC22A1
and SLC22A2 (Fig 5A).
Data from Ensembl [45, 46] revealed that SLC22A24 1:1 orthologs were present in some,
but not all mammals, and were absent in non-mammalian vertebrates (e.g., fish, reptiles and
birds). Fig 5B shows the phylogenetic analysis of ten SLC22A24 1:1 orthologs in mammals
along with other relevant organic anion transporters in the SLC22 family (see also S5 Fig).
Included in the figure are SLC22A24 orthologs from apes (orangutan, chimpanzee, gorilla and
gibbon), lemur (mouse lemur and coquerels sifaka), rabbit, and horse. We compared the func-
tion of the human SLC22A24 with ortholog representatives from the different branches of the
phylogenic tree (Fig 5C), that of the horse, mouse lemur, and rabbit. We also included the rat
Slc22a9/Slc22a24, previously known as Slc22a19 and Slc22a9, but most recently assigned the
gene name Slc22a24 [47]. All five species (human, horse, mouse lemur, rabbit, and rat) showed
significant uptake of estrone sulfate (>2.5 fold) compared to EV transfected cells (Fig 5C).
There were substrate specificity differences between the human SLC22A24 and the orthologs
of the other species investigated with the largest differences between the rat orthologs and the
other species. Notably, horse SLC22A24 significantly transports taurocholic acid (~2 fold),
estrone sulfate (~3 fold), and estradiol-17-glucuronide (~2 fold), but not androstanediol glucu-
ronide (~1.2 fold). Mouse lemur SLC22A24 transports estrone sulfate (~17 fold), androstane-
diol glucuronide (~2 fold) and estradiol-17-glucuronide (~11 fold) but not taurocholic acid.
Rabbit SLC22A24 significantly transports taurocholic acid (~11 fold), estrone sulfate (~5 fold),
androstanediol glucuronide (~4 fold), and estradiol-17-glucuronide (~2 fold). In contrast, rat
Slc22a9/Slc22a24, which has the lowest sequence similarity to human protein of the four spe-
cies, does not significantly transport taurocholic acid or androstanediol glucuronide.
We also determined the plasma membrane expression of each of the above orthologs in
HEK293 cells using a GFP-tag to ensure the proper localization of the expressed proteins (S6
Fig). All five orthologs were expressed on the plasma membrane, but the expression levels
were variable. More pronounced plasma membrane expression was observed for the rabbit
and human orthologs. The horse, rat, and the mouse lemur orthologs, were also present on the
plasma membrane, but had a more diffuse intracellular expression (S6 Fig).
Two SLC22A24 isoforms exhibit no significant differences in their
substrate selectivity, while SLC22A24 p.Tyr501Ter variant exhibits no
protein expression or transport function
According to UniProt, Ensembl, and NCBI RefSeq, the SLC22A24 transcript is identified in
three major isoforms. Specifically, ENST00000612278.4 (552 amino acids, NM_001136506,
A0A087WWM3), identified in this paper as the reference SLC22A24, ENST00000417740.5
(551 amino acids, no known NCBI reference, C9JC66), identified as SLC22A24-551, and
ENST00000326192.5 (322 amino acids, NM_173586, Q8N4F4), identified as SLC22A24-322.
The short SLC22A24-322 isoform was omitted from further analysis due to its lack of transport
activity, expression from GFP fusion construct, and absence of key structural motifs (see S7
Fig). Transcripts of the two isoforms (SLC22A24 and SLC22A24-551) were detected using
PCR and the sequences were confirmed. The SLC22A24-551 isoform exists due to the presence
of two potential AG acceptor sites at the splice junction between exons 9 and 10, (indicated as
position “1” or “2” on S8A Fig), thus resulting in two different splice variants. The splice
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variants differ in two amino acids in position 533 and 534 (S8B Fig). Functional characteriza-
tion of SLC22A24 and SLC22A24-551 indicated no significant differences in their uptake func-
tion. In particular, a similar fold-uptake over control between the two isoforms was observed
for all representative steroid glucuronides, steroid sulfates, bile acids, methotrexate and suc-
cinic acid (Fig 6A).
Next, we characterized the nonsense variant in SLC22A24, which is associated at genome-
wide significance levels with androsterone glucuronide and etiocholanolone glucuronide (Fig
1). A survey of the 1000 Genomes Project Phase 3, revealed that the G-allele of rs11231341,
coding for p.Tyr501Ter, is the major allele, ranging from 51% in Mende in Sierra Leone to
92% in Peruvian in Lima, Peru [48]. In addition, the G-allele is the major allele (80%) in indi-
viduals from the Greater Middle East (GME) (The GME Variome Project, http://igm.ucsd.
edu/gme/). Cells transiently transfected with SLC22A24 p.Tyr501Ter exhibited no transport
function (Fig 6B). Consistent with the uptake studies, GFP-tagged SLC22A24 localized to
the membrane, while GFP-tagged SLC22A24 p.Tyr501Ter did not (Fig 6C). Further, plasma
membrane protein expression was evaluated using Western blots for HEK293 Flp-In cells
stably expressing SLC22A24 or transiently transfected with either empty vector only (EV,
pCMV6-Entry), SLC22A24, or SLC22A24 p.Tyr501Ter (S9 Fig). All samples expressed the
Fig 6. Uptake of various anions by two SLC22A24 isoforms and the effect of a common nonsense variant, p.Tyr501Ter on uptake and plasma
membrane localization. (A) Fold uptake over empty vector for different substrates. HEK293 Flp-In cells were transiently transfected with different
constructs containing SLC22A24 or SLC22A24-551. The experiments were repeated at least one time. Data represents means ± S.D. of two independent
experiments. Underlying data are provided in S1 Data. (B) Transport activity for different substrates was compared in HEK293 Flp-In cells transiently
transfected with SLC22A24 or SLC22A24 p.Tyr501Ter. The uptake of SLC22A24-expressing cells was set to 100%. Underlying data are provided in S1
Data. Data represents means ± S.D. from three wells. The experiments were repeated one time and similar results were obtained. (C) Membrane
localization of SLC22A24 and SLC22A24-Y501Ter. HEK293 cells were transiently transfected with GFP fusion constructs and visualized by confocal
microscopy.
https://doi.org/10.1371/journal.pgen.1008208.g006
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positive control, Na+/K+-ATPase. SLC22A24 was expressed in both the stable cell sample as
well as the transiently transfected cells. SLC22A24 p.Tyr501Ter was not detected on the plasma
membrane of the transiently transfected cells, despite having detectable mRNA levels (S9 Fig).
Transcriptomic and proteomic studies reveal low and variable expression
levels of multiple isoforms of SLC22A24
Transcriptomic studies. PCR identified the transcripts to be expressed at variable levels
in the 14 tissues tested (pooled from various samples, see S7 Table), in addition to kidney and
liver (Fig 7A). SLC22A24 and SLC22A24-551 were found at moderate levels in nine tissues
including total brain, liver, skeletal muscle, kidney, pancreas, colon, spleen, testis, and thymus
(Fig 7A). Interestingly, the Kidney Interactive Transcriptomics database, which is a repository
for single cell RNAseq data from human kidney, shows SLC22A24 to be expressed specifically
in the proximal tubule segment 3 (S3), and not in other regions of the human kidney (http://
humphreyslab.com/SingleCell/search.php, Fig 7B)[49], providing support for low overall tran-
scriptomic expression in the kidney.
Proteomic studies. Using LC-MS/MS Selective Reaction Monitoring (SRM) approach,
we evaluated protein levels of the two SLC22A24 isoforms in 20 renal cortical samples from
self-reported African Americans (age [mean ± SD]: 13 ± 8 years; 50% males). SRM is a sensi-
tive mass spectrometry technique that is capable of accurate protein detection and quantifica-
tion [50]. Three peptides were designed to detect and quantify the protein abundance (S10
Fig). Peptide 1 detected both SLC22A24 and SLC22A24-551, while peptides 2 and 3 were spe-
cific to SLC22A24 and SLC22A24-551, respectively. Surprisingly, isoforms SLC22A24 and
SLC22A24-551 exhibited a mutually exclusive expression pattern (S8 Table), that is, each indi-
vidual sample expressed only one of the two isoforms. Genotyping 20 renal cortical samples
from African Americans, we identified the c.1503-G allele to have an allele frequency of 67.5%
(Hardy-Weinberg p-value = 0.4), consistent with known allele frequencies in publicly available
sources. Ten c.1503-GG, seven c.1503-GT, and three c.1503-TT were used for the SRM analy-
sis (SLC22A24 c.1503-GG codes for SLC22A24 p.Tyr501Ter homozygotes). In line with the
stop codon at amino acid position 501, the SRM analysis showed that the renal cortical tissues
with the genotype c.1503-GG have no detectable protein abundance using peptides 2 and 3
(S8 Table).
Discussion
Steroids including sex steroids and glucocorticosteroids have pleiotropic actions in reproduc-
tive and other tissues in the body and impact numerous biological processes [1, 53, 54]. In par-
ticular, they influence body composition, glucose and lipid metabolism, cardiovascular and
immunological functions, and reproductive fitness [54]. Accordingly, there is a vast literature
focused on the study of the action, regulation, metabolism and disposition of steroids [1].
GWAS have revealed a number of genes that are involved in steroid metabolism and hormone
binding as the major determinants of interindividual variation in the levels of many steroids
and steroid conjugates [2–7, 55]. Intrigued by the association of a novel locus and an orphan
transporter, SLC22A24, with metabolite levels in metabolomic GWAS, we performed experi-
mental studies along with a computational analysis to functionally characterize the transporter
and further understand its physiological role. Our studies led to four major findings. First,
SLC22A24 is an organic anion transporter, consistent with multiple GWAS focused on metab-
olites, and validated through comparative structure models, cell-based metabolomic screens,
and functional studies. Second, SLC22A24 is conserved among higher order primates, but has
diverged within lower level primates and other mammals. Third, two functional isoforms of
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Fig 7. Expression of SLC22A24 mRNA transcripts in human tissues and cells, and a proposed model for its functional role in the
disposition of steroid conjugates in the kidney. (A) Expression of SLC22A24 mRNA in various pooled samples was detected by RT-PCR. 40
and 30 cycles were used for amplifying SLC22A24 and GAPDH mRNA, respectively. (B) SLC22A24 expression from human kidney single cell
datasets (Healthy Human Adult Kidney (Complete: 4,524 nuclei)) were obtained from Kidney Interactive Transcriptomics (http://
humphreyslab.com/SingleCell/)[51]. Two different plots (i and ii) from the online analyzer for kidney single cell datasets, show the regions of
the kidney and the abundance of SLC22A24 mRNA transcripts. EC, endothelial cell; PT, proximal tubule; LH(AL), loop of Henle ascending
loop; LH(DL), loop of Henle descending loop; DCT, distal convoluted tubule; CNT, connecting tubule; PC, collecting duct-principal cell;
IC-A, intercalated cell type A; IC-B, intercalated cell type B. Overall, the plots indicate that SLC22A24 is selectively expressed in the proximal
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SLC22A24 are detectable in the human kidney, and the transporter has a highly specific
expression pattern in the nephron, localized to segment 3 of the proximal tubule. Fourth, the
transporter has a common nonsense variant, p.Tyr501Ter (rs11231341), which is found at
high allele frequencies in human populations, and is associated with low steroid and steroid
conjugate levels (p<5x10-8). Below we discuss each of the major findings in detail.
The first major finding of the study is that SLC22A24 is an organic anion transporter (Figs
2 and 3). Based on results the GWAS (Fig 1), metabolomic profiling and comparative structure
modeling (Fig 2), we hypothesized and validated in our in vitro and cellular metabolomic stud-
ies that SLC22A24 preferentially transports organic anions. However, it does not transport a
number of organic anions transported by other organic anion transporters in the SLC22 family
(SLC22A6, SLC22A7 and SLC22A8). For example, we did not detect transport of uric acid,
tenofovir, cGMP, or alpha-ketoglutaric acid, which are canonical substrates of SLC22 organic
anion transporters (S5 Table) [20, 56]. Further, our results showed that SLC22A24 is Cl-depen-
dent (Fig 3E). A similar chloride dependency has been observed for URAT1 (SLC22A12), a
major uric acid reabsorptive transporter in the kidney [57], and OAT4 (SLC22A11), which
uses the downhill flux of chloride ions to move its organic anion substrates across the apical
membrane of the renal proximal tubule [37, 58]. Similar to OAT1 (SLC22A6), OAT3
(SLC22A8) and OAT4 (SLC22A11), SLC22A24 was also trans-stimulated by glutaric acid [37,
38, 59, 60], but not significantly by succinic acid and alpha-ketoglutaric acid (Fig 3F). In con-
trast, OAT1 and OAT3 are trans-stimulated by alpha-ketoglutaric acid as well as glutarate,
consistent with a broader selectivity of these two transporters in comparison to SLC22A24.
Our second finding is that many species, including lower level primates and rodents, do not
have orthologs of SLC22A24. Phylogenetic analysis reveals the presence of SLC22A24 ortho-
logs in apes, lemur, and certain other mammalian species, but none in rodents. Human
SLC22A24, located on chromosome 11q12, falls within a cluster of other SLC22 family genes
called the Unknown Substrate Transporters (USTs), consisting of SLC22A9, SLC22A10, and
SLC22A25. Sequence comparison indicates that human SLC22A24 is distant from those in
mice and rats (mouse USTs include Slc22a26, a27, a28, a29, a30, a9/a19; rat USTs include
Slc22a9/a24, a9/a25, Ust4r, Ust5r) (Fig 5A, S5 Fig) and only 11 species have direct orthologs of
the human SLC22A24 (see ref. [46], Ensembl database (version 95)). Previous studies have
characterized the function of human liver specific SLC22A9 (OAT7)[25], several rodent USTs,
including the rat kidney Slc22a9/a24 (Oat5) [61], rat kidney Slc22a9/a25 (Ustr1/Oat8) [62, 63],
mouse kidney Slc22a9/a19 (Oat5) [64–66], and mouse liver and kidney Slc22a30 (Oat9) [67].
All of the above transporters transport steroid sulfate conjugates and some other anions, such
as ochratoxin A. However, they do not transport and are not inhibited by steroid glucuronide
conjugates, which are substrates and inhibitors of the human SLC22A24 [61, 63]. Consistent
with these results, steroid glucuronides are not detectable in rat urine but are detectable in
human urine [68]. Further, glucuronidated steroids are not detected in serum samples from
rodents [69].
Our third finding is that the functional isoforms of the human SLC22A24, are expressed at
lower levels in kidney and liver tissues compared to other known kidney-specific anion trans-
porters from the SLC22 family, e.g., SLC22A6, SLC22A8, SLC22A11, and SLC22A12, as noted
from the RNA-seq data generated by the Human Protein Atlas (HPA)[70] and the Genotype-
tubule segment 3 (PT(S3)). (C) Proposed mechanism of steroid glucuronide handling in the kidney by SLC22 transporters. The scheme
illustrates the proposed hypothesis that SLC22A24 is on the apical membrane of the proximal tubule and functions in the reabsorption of
steroid glucuronides. Conversely, SLC22A8, localized to the basolateral membrane, functions in the secretion of steroid glucuronides[52].
Future studies are needed to precisely localize the transporter to the apical or basolateral membrane. This scheme was created with BioRender
(https://biorender.com/).
https://doi.org/10.1371/journal.pgen.1008208.g007
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Tissue Expression (GTEx) consortium (see S10 Table). Though expressed at lower levels, the
primary finding that genetic variants in SLC22A24 associate with plasma levels of several
metabolites (S1 Table), suggests that the transporter plays a critical and specific role in deter-
mining systemic levels of metabolites. The narrower substrate selectivity of SLC22A24 as com-
pared to other SLC22 organic anion transporters, SLC22A6 and SLC22A8, which are broadly
selective, further supports a specific role for the transporter in the kidney. The Kidney Interac-
tive Transcriptomics database (http://humphreyslab.com/SingleCell/search.php) shows
SLC22A24 to be expressed specifically in S3 (Fig 7B) and not in the other regions of the
human kidney, which suggests that SLC22A24 plays a specific role in the kidney in comparison
with other renal organic anion transporters in the SLC22 family. The selective localization of
SLC22A24 in the human kidney is consistent with the renal localization of rodent USTs,
which are expressed in particular sub-regions of the kidney [61, 63, 65]. For example, rat
Slc22a9 is expressed on the apical membrane of the collecting duct [63], and mouse Slc22a9/
a19 is expressed on the apical membrane of the proximal tubules of the outer medulla [61, 65].
Collectively, the data suggest a specific role for SLC22A24 in the kidney, reminiscent of USTs
in rodents, which do not express SLC22A24.
Our fourth finding is that the transporter has a common nonsense variant, p.Tyr501Ter
(rs11231341), which is found at high allele frequencies in human populations, and is a major
determinant of inter-individual variation in plasma levels of certain steroid and steroid conju-
gates (p<5x10-8). Premature stop codons sometimes trigger nonsense-mediated decay
(NMD), which in this case might cause a rapid degradation of the SLC22A24 transcripts and
result in the observed lack of detectable protein signal in the kidney samples from individuals
who are homozygous for p.Tyr501Ter (S8 Table). The overall low mRNA transcript levels of
SLC22A24 in publicly available databases (which either average expression levels from multi-
ple samples or report results of pooled samples) may be due to the high allele frequency of the
rs11231341 encoding the p.Tyr501Ter. Surprisingly, the premature stop codon has not been
found in primates[71] (61 chimpanzee, 10 bonobo, 43 gorilla, 9 orangutan). However, accord-
ing to the three ancient human genomes, the Altai Neandertal, Denisova, Ust-Ishim and Vin-
dija, the ancient humans were either p.Tyr501Ter homozygous or heterozygous (available
from the ancient genome browser, https://bioinf.eva.mpg.de/jbrowse/)[72, 73]. These data
suggest that the mutation was introduced in the ancient human period, the reason for which
remains an open evolutionary question.
Examination of GWAS and publicly available databases (GWAS Catalog, NCBI Phenotype-
Genotype Integrator) revealed strong associations between SNPs in SLC22A24 and plasma lev-
els of various metabolites, particularly those of steroid glucuronide conjugates (S1 Table), as
well as steroid sulfate conjugates (S1 Table[25]). SLC22A24 p.Tyr501Ter (rs11231341), which
has no transport activity and no protein expression on the plasma membrane (Fig 6), is associ-
ated with lower plasma levels of steroid glucuronides in three independent cohorts and in mul-
tiple ethnic groups (Table 1). Thus, it is reasonable to speculate that individuals harboring p.
Tyr501Ter would have reduced plasma steroid glucuronide levels due to their reduced ability
to reabsorb these metabolites. Interestingly, we observed that SLC22A24 possesses a PDZ-con-
sensus motif at its C-terminal, which is also present in several known transporters localized to
the apical membrane of the renal proximal tubule [74, 75] (S11 Table). The presence of this
motif supports the direction of the observed associations and the idea that the transporter
functions in the reabsorption of steroid conjugates in the kidney. Although it has been shown
that the ABC transporters in the proximal tubule, MRP2 and MRP3 function in the efflux of a
steroid conjugates into the urine and plasma, respectively[76], to our knowledge, there have
been no reports characterizing renal reabsorptive SLC transporters for steroid glucuronide
conjugates. Glucuronide conjugates of steroids normally undergo net secretion in the
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proximal tubule, presumably by MRP2 and the organic anion transporters, OAT1 and OAT3
[76]. Though our data suggest that SLC22A24 functions in the reabsorption of steroid metabo-
lites in the kidney, future studies are needed to confirm its role. In particular, measurements of
steroid metabolites in both urine and plasma are required to understand the role of the trans-
porter in their renal clearance. Unfortunately, urinary levels of steroid conjugates were not
available in ARIC, which was used as our discovery cohort.
The highly significant association between the SLC22A24 nonsense variant and androster-
one glucuronide levels led us to examine associations between the variant and diseases that are
known to be associated with this metabolite. Through a phenome-wide scan of multiple pub-
licly available sources, we observed associations between SLC22A24 and conotruncal heart
defect (p = 1x10-6)[77], lipid levels, and cardiovascular disease (p-values range from 1x10-5 to
9x10-5, data source Phenotype-Genotype Integrator, https://www.ncbi.nlm.nih.gov/gap/
phegeni). In addition, we used phenome-wide association study (PheWAS) approach to ana-
lyze the many phenotypes in UKBiobank (http://geneatlas.roslin.ed.ac.uk/phewas/) with
SLC22A24 SNPs that are associated with steroid and steroid conjugate levels, rs11231341 (p.
Tyr501Ter) and rs78176967 (S12 Table). Hematological measurements (e.g. immature reticu-
locyte fraction, neutrophil percentage) are among the top traits that are significantly associated
with the two SNPs (S12 Table). These traits have been previously associated with steroid hor-
mones [78–81]. Further, studies have shown that levels of androsterone glucuronide are ele-
vated in women with acne and/or hirsutism [82–87]. Through a detailed search of associations
with acne and/or hirsutism, we noted that the top SNPs in the SLC22A24 locus associated with
acne (p = 0.001) in the UKBiobank[88] are among the top SNPs significantly associated with
steroid and steroid glucuronide levels (S13 Table). Overall, the identified phenotypic data is
consistent with the idea that dysregulation of steroid hormone metabolism contributes to the
presentation of acne, blood traits, and cardiovascular disease in humans (S12 and S13 Tables).
In conclusion, these studies represent the first functional characterization of SLC22A24, a
transporter in the UST (Unknown Substrate Transporter) region of the genome. The trans-
porter has a unique substrate specificity and our studies suggest that it functions in the reab-
sorption of steroid glucuronide conjugates in the kidney (Fig 7C). This work represents an
important step in the global effort to functionally characterize the remaining members of the
SLC22 family.
Materials and methods
Sources used to determine associations between genetic variations in
SLC22A24 and human traits and diseases
Various public sources were used to obtain significant associations of SNPs within SLC22A24
gene +/- 50,000 kb (chr11:62553988–62743269 (hg18); chr11: 62797412–62986693 (hg19);
chr11:63029940–63219221 (hg38)) with clinical variables related to metabolites levels. These
sources included the GWAS Catalog, Phenotype-Genotype Integrator, GRASPS, GWAS Meta-
bolic Server (http://metabolomics.gwas.eu) and others. The results from the search in public
sources are shown in S1 Table.
Further association analyses of steroid metabolite levels in the
Atherosclerosis Risk in Communities Study (ARIC)
An application was approved by the ARIC Publication Committee to determine the associa-
tions of SLC22A24 variants with steroid and bile acid metabolites in ARIC cohort (Manuscript
proposal #3167). Below we described the ARIC study population used in this association
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analyses, metabolite measurement and association analyses of selected SNPs and metabolites
relevant to this study. Study population: The ARIC is a prospective epidemiologic study con-
ducted in U.S., designed to investigate the etiology and natural history of atherosclerosis, the
etiology of clinical atherosclerotic diseases, and variation in cardiovascular risk factors, medi-
cal care and disease by race, gender, location, and date[89]. Using this cohort, investigators
have published several papers related to associations between serum metabolome and diseases
or traits among the subjects in the ARIC study[90]. In general, each visit included interviews
and a physical examination [89]. In 2014, Metabolomic profiles were measured in baseline
serum from 599 African- and 1,553 European-Americans. Participants were excluded if they
did not give consent for use of DNA information. Assessment of Metabolomic Profiles: Methods
for the assessment of metabolomics profiles, and whole exome sequencing were described pre-
viously [91–93]. In brief, metabolites were completed by Metabolon Inc. (Durham, USA)
using an untargeted, gas chromatography-mass spectrometry and liquid chromatography-
mass spectrometry (GC-MS and LC-MS)-based metabolomic quantification protocol. The
annotated exome was captured by NimbleGen’s VCRome2.1 (Roche NimbleGen), and the
captured exons were sequenced using Illumina HiSeq 2000. A total of 573 African Americans
and 1375 Caucasians were available for the association analyses. The primary analysis was to
determine the association of rs11231341 (SLC22A24 p.Tyr501Ter) with androsterone glucuro-
nide (X-22379) and etiocholanolone glucuronide.
Association of steroid glucuronide in Middle Eastern population
Yousri NA et al. have published the whole exome sequencing to identify genetic polymor-
phisms associated with metabolite levels in Middle Eastern population[9]. Using the data
computed from Yousri NA et al.[9], the beta and p-value for the association of SLC22A24 p.
Tyr501Ter (rs11231341) with androsterone glucuronide (X-22379) and etiocholanolone glu-
curonide are shown in Table 1.
Establishment of transient and stable cell lines
Human embryonic kidney cell lines (HEK293) containing a Flp-In expression vector
(HEK293 Flp-In) were used to create either transient or stable cell lines expressing SLC22A24
cDNA or vector only DNA. SLC22A24 (NM_173586 and NM_001136506) tagged open read-
ing frame (ORF) clone and vector control (pCMV6-Entry) were purchased from OriGene.
These vectors were either transiently transfected or stably transfected into Flp-In 293 cells
using Lipofectamine LTX (Thermo Fisher Scientific). 500 ng of DNA and 1 μL of Lipofecta-
mine LTX or 10 μg of DNA and 44 μL of Lipofectamine LTX were used for transfection into
each well of the 24-well plate (seeding density 2.0x105 cells/well) or 100 mm tissue culture
plate (seeding density 4x106 cells/well) respectively. More detailed methods to create stably or
transiently transfected cells have been described from our groups (see [26, 38, 94]). For tran-
sient transfection, after 36 to 48 hours, cells were use for transporter studies (see section called
Transporter uptake studies) or for protein quantifications (see section called Analysis of
SLC22A24 protein levels in transiently expressing HEK293 cells.). For stable cell lines, after 48
hours, cells were transferred to a new 100 tissue culture plate and were treated with 500 μg/mL
Geneticin. Fresh media containing 500 μg/mL Geneticin was replaced each day.
Cloning and expression profiling of SLC22A24 in liver and kidney
For the cloning, pooled total RNA of human kidney and liver were purchased from Clontech.
Total RNA (2 μg) from each sample was reverse transcribed into cDNA using SuperScript
VILO cDNA Synthesis kit (Thermo Fisher Scientific) according to the manufacturer’s
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protocol. For the expression profiling of SLC22A24, the cDNA from pooled human tissues
was purchased from Takara Bio Inc. In particular the cDNA from two tissue panels was pur-
chased, Human MTC Panel I and II. S7 Table shows the primers that were used in the PCR
to clone the transcripts, NM_173586 and NM_001136506. PCR products were cloned into
pcDNA5FRT and sequenced (MCLAB, South San Francisco) to confirm the transcript. In
addition, the primers that were used in the PCR to detect the presence of GAPDH (housekeep-
ing gene) and the three SLC22A24 isoforms are shown in S7 Table. For expression profiling
study, 10 ng cDNA of various tissues (Takara Human MTC panel I & II) were used for each
reaction and amplified by KOD Xtreme Hot Start DNA polymerase kit (Takara). The PCR
cycling conditions used are: (i) activation at 94˚C for 2 min, (ii) denature at 98˚C for 10 sec,
(iii) annealing at 57.5˚C for 30 sec and (iv) extension at 68˚C for 1 min.
RNA isolation and quantitative RT-PCR
HEK293 Flp-In cells were grown in 24-well poly-D-lysine coated plates (seeding density
of 1.5–1.8 x105/well) until 75–80% confluency. Upon reaching confluency, cells were tran-
siently transfected with vector only or vector containing different SLC22A24 isoforms (in
pCMV6-Entry expression vector). The different isoforms were: SLC22A24 with 552 amino
acids (NM_001136506.2, ENST00000612278.4), SLC22A24-551 with 551 amino acids
(NM_001136506.2, ENST00000417740.5) and SLC22A24-322 with 322 amino acids
(NM_173586.2) and SLC22A24 p.Tyr501Ter (c.1503T>G) (in both pCMV6-Entry and
pcDNA5FRT vector backbone). 500 ng of the plasmid DNA, 1 μL of Lipofectamine LTX
(Thermo Fisher Scientific) and 100 μL of the Opti-MEM I reduced serum media (Thermo
Fisher Scientific) were used in the transfection mixture. 40 hours after transfection, media
was removed and 350 μL of RNA Lysis buffer was added to each well. Total RNA was isolated
using the Qiagen RNeasy kit (Qiagen). cDNA was synthesized using SuperScript VILO cDNA
Synthesis Kit (Thermo Fisher Scientific). Quantitative RT-PCR (qRT-PCR) was performed
using Taqman reagents and specific primer and probe sets for human SLC22A24 (Assay ID:
Hs00543210_m) and GAPDH (Assay ID: Hs99999905_m1) (Applied Biosystems, Foster City,
CA). Reactions were performed in a 96-well plate with a 10 μL reaction volume using an ABI
7900HT Fast Real-time PCR system (Applied Biosystems) using the default instrument set-
tings. Expression levels were determined from three independent biological samples using
the Ct method after normalization to endogenous levels of GAPDH[56, 95]. The results are
expressed as a fold increase of the SLC22A24 mRNA level over the cell lines expressing the vec-
tor control.
Synthesis of SLC22A24 ortholog cDNA
Sequences of SLC22A24 orthologs from mouse lemur (Microcebus murinus, Transcript ID
ENSMICT00000042921.1), rabbit (Oryctolagus cuniculus, XM_002720992.3, Transcript ID
ENSOCUT00000010486.2), and horse (Equus caballus, Transcript ID ENSECAT00000014835.1)
were obtained from ensembl.org (release 95)[45] and the National Center for Biotechnology
Information (NCBI). The cDNA of the gene was synthesized by GeneScript and inserted into
the BamHI and XhoI restriction sites on the expression vector pcDNA5FRT (Invitrogen). The
cDNA of the rat Slc22a9/Slc22a24 (NM_173302.1) was purchased from OriGene (Catalog num-
ber: RR202601). The synthesized SLC22A24 ortholog cDNA clones were used to make GFP
fusion constructs to determine their subcellular localization. The GFP coding sequence was
ligated to the 3’ end of the SLC22A24 ortholog cDNA in the expression vector pcDNA5/FRT
using In-Fusion HD cloning kit (ClonTech #639642). The human SLC22A24 GFP fusion con-
struct was purchased from OriGene (Catalog number: RG227944). The primers used to clone
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the GFP fusion constructs for the other non-human species are shown in S9 Table. The sequence
of the constructs was confirmed by sequencing (MCLAB, South San Francisco).
Transporter uptake studies
HEK293 Flp-In cells stably or transiently transfected with SLC22A24 were seeded at a density
of 180,000 to 200,000 cells/0.5 mL in poly-D-lysine 24-well plates approximately 16 to 24
hours prior to uptake studies. For uptake studies in transiently expressing SLC22A24, methods
described in previous section were performed before this study. Before the uptake studies, the
culture medium (Dulbecco’s modified Eagle’s medium, DMEM H-21, supplemented with 10%
fetal bovine serum) was removed and cells were incubated in 1.0 mL HBSS for 10–20 min at
37 ˚C. For the screening of radiolabeled compounds as substrate of SLC22A24, trace amount
of the radiolabeled compounds (3H or 14C) were diluted in the HBSS (1:2000 or 1:3000) for
uptake experiments. The details of the compound concentrations and uptake time are
described in the results or figure legends. Uptake reactions were terminated by washing cells
twice with 1 mL HBSS buffer and the cells were incubated in 700–800 μL of lysis buffer (0.1 N
NaOH, 0.1% v/v SDS) and then 650–750 μL of cell lysate was transferred to scintillation fluid
for scintillation counting. Experimental condition used in this study was similar to transporter
assays published previously by our group[95, 96]. For pH dependence experiments, HBSS
buffer was adjusted to different pHs (5.5, 7.4 and 8.5) by adding hydrochloric acid or sodium
hydroxide[38]. For chloride dependence study, two different uptake buffers were used: (1)
chloride free buffer (125 mM sodium gluconate, 4.8 mM potassium gluconate, 1.2 mM magne-
sium sulfate, 1.3 mM calcium gluconate, and 5 mM HEPES; adjusted with sodium hydroxide
to pH 7.4); or (2) sodium buffer (125 mM sodium chloride, 4.8 mM potassium chloride, 1.3
mM calcium chloride, 1.3 mM magnesium sulfate, and 5 mM HEPES, adjusted with sodium
hydroxide to pH 7.4)[95, 97]. For trans-stimulation studies, experimental conditions described
in our previously published methods were used[38]. In brief, the SLC22A24 or EV stable cell
lines were pre-incubated with either buffer or 2 mM succinic acid, 2 mM α-ketoglutaric acid
or 2 mM glutaric acid for 2 hours. Then, the cells were washed twice with HBSS before initiat-
ing uptake of the anions (estrone sulfate, estradiol glucuronide, androstanediol glucuronide or
taurocholic acid).
Kinetic studies of steroid conjugates and bile acid transport by SLC22A24
We characterized the kinetics of the three steroid conjugates and two bile acids by SLC22A24,
discovered from the initial screening. We selected SLC22A8 for comparison to SLC22A24 due
to the significant accumulation of steroid conjugates by SLC22A8. The kinetic studies were
performed following methods developed in our group[38]. In brief, these studies were per-
formed using stable cell lines expressing SLC22A24 (NM_001136506) or SLC22A8[98]. For
the kinetic studies of bile acid, only SLC22A24 expressing cells were used, as bile acids are
poor substrates of human SLC22A8[99]. For each substrate, we varied the concentrations
of the unlabeled compounds. The uptake rate was evaluated at 1 minute, as this fell within
the linear range in the uptake versus time plot for each substrate. Each point represents the
mean ± SD uptake in the transporter-transfected cells minus that in empty vector cells. The
plots show the result for a representative experiment of n = 2.
Inhibition of SLC22A24-mediated uptake by various anions and drugs
HEK293 Flp-In cells stably transfected with SLC22A24 (NM_001136506) were seeded at a
density of 200,000 to 220,000 cells/0.5 mL in poly-D-lysine 24-well plates approximately 16 to
24 hours prior to the experiments. On the day of the experiments, cells were washed with 1 mL
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of Hank’s buffered salt solution (HBSS) per well and then preincubated for 10–20 min in the 1
mL of HBSS buffer. To assess inhibition, the cells were incubated with uptake buffer (1 μM
unlabeled taurocholic acid and trace amount of [3H]-taurocholic acid in HBSS) containing
either 100 μM estrone sulfate as positive control, 1% DMSO as negative control or 100 μM of
the selected test compounds. Each of the 24-well plates contained negative and positive con-
trols. Uptake of [3H]-taurocholic acid was stopped after 10 min by washing twice with ice-cold
HBSS. The cells were lysed in 900 μL of lysis buffer (0.1 N NaOH and 0.1% SDS in double dis-
tilled water) per well while shaking for up to 90 min. 820 μL of the lysate was then added to 2.5
mL of EcoLite scintillation fluid (MP Bio), and the radioactivity was determined on a LS6500
Scintillation Counter (Beckman Coulter). Values were corrected for protein concentration as
determined with a BCA assay kit (Thermo Scientific, Rockford, IL). All values were deter-
mined in triplicate, and final values are expressed as % uptake relative to negative control (1%
DMSO). Methods used in the inhibition studies were from previous studies in our laboratory
[100, 101]. The test compounds were tested at least one time and some compounds were
selected to test two or three times to check for consistent results.
Analysis of SLC22A24 protein levels in transiently transfected HEK293
cells
A 100 mm tissue culture plate of HEK293 Flp-In cells was transiently transfected with the
following expression vectors: vector only (pCMV6-Entry), SLC22A24 (NM_001136506),
SLC22A24-322 (NM_173586), SLC22A24 p.Tyr501Ter (created using site directed mutagene-
sis). All proteins contained a C-terminal Myc-DDK tag. For evaluation of the SLC22A24 pro-
tein levels, cell lysates were collected 48 hours after transfection. Plasma membranes were
separated from intracellular membrane using the Plasma Membrane Protein Extraction Kit
(Abcam ab65400)[32]. Transfected cells were harvested in 2 mL of homogenization buffer.
Cells were homogenized using the syringe-based homogenization method. A needle (27
gauge) was attached to a 1 mL syringe. The cells lysates were passed through the syringe 5
times. A higher gauge needle, 30 gauge, was then used and the suspension was passed through
for 5 additional times. The plasma membrane fraction was resuspended in 50 μL lysis buffer.
Cell samples were deglycosylated using PNGase F (NEB P0708L) per the manufacturer’s
protocol.
Plasma membrane localization studies
The resulting GFP fusion constructs were transiently transfected in human embryonic kidney
293 (HEK293) cells. The cells were maintained in Dulbecco’s modified Eagle’s Medium
(DMEM) (Fisher) supplemented with 10% fetal bovine serum (FBS) (Invitrogen) and 10 mM
HEPES (Fisher). Dr. R. Irannejad’s laboratory has established standard methods for transfect-
ing HEK293 cells for membrane localization studies[102–104]. HEK293 cells were grown to
~70% confluence in poly-L-lysine coated glass coverslips in 12-well plates. The cells were tran-
siently transfected with 1 μg plasmid DNA with 2 μL of Lipofectamine 2000 (Thermo Fisher
Scientific). 24-hours after transient transfection, cells were fixed in 4% paraformaldehyde.
Coverslips were mounted using ProLong Gold Antifade Mountant (Thermo Fisher Scientific)
on glass microscope slides and visualized using Yokogawa CSU-22 Spining Disk Confocal
microscope (Nikon Instruments, Inc).
Metabolomic study
Samples of cell pellets from HEK293 Flp-In were prepared and sent to Metabolon Inc. (North
Carolina, USA) for metabolites measurement using Metabolon platform. Cell pellet samples
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were prepared from five 100 mm culture dishes each of HEK293 Flp-In stably expressing vec-
tor only (pCMV6-Entry) or cells transiently expressing SLC22A24 cDNA (NM_001136506).
24 hours after transient transfection, media were removed and DMEM-H21, phenol red free,
media (Invitrogen) containing 20% Fetal Bovine Serum, U.S.D.A. Approved Origin (Product
Number 89510–186, Lot Number 356B16) were added to each dish. 48 hours after transient
transfection, the cells were washed twice with cold PBS, and cells were scraped and transferred
to a 15 mL falcon tubes. Tubes were centrifuged at 3000 rpm and supernatant were removed
and stored the cell pellet in -80 ˚C freezer until shipping to Metabolon Inc. for metabolomics
measurement (see[26] to obtain methods for metabolomic study).
Metabolomic data analysis
Raw metabolomic data were processed by Metabolon[105]. Individual metabolites were
quantified and the values normalized. A two-tailed t-test was performed between EV and
SLC22A24 and between EV and SLC22A1. False discovery rate (FDR) was used to correct the
p-values. We eliminated potential false positive metabolites using the following criteria: if
FDR< 0.05 between SLC22A24 and EV cells, but p-value > 0.05 between SLC22A1 and EV
cells, the metabolites were considered false positives. The results of the analysis are included in
S3 Table.
Clustering of human SLC22A24 and other species orthologs in the SLC22
family
Three phylogenetic trees were constructed. The first consists of the UniProt amino acid
sequences for the human SLC22 family members with known substrates, human SLC22
members in the gene cluster between SLC22A8 and SLC22A9 of the human chromosome
11q12.3 (hg19 assembly), and all identified mouse and rat SLC22 members (Fig 5A). The sec-
ond and third tree were built focusing on anion transporters. The second tree (Fig 5B)
includes the human SLC22A24, known SLC22A24 orthologs in other species identified in
the UniProt, known human anion transporters in SLC22 family (SLC22A6, A7, A8, A9, A11
and A12), genes in the human chromosome 11q12.3 (SLC22A10, A25), mouse anion trans-
porters (Slc22a6, a7, a8, a9/a19, a9/a21, a12), mouse Slc22 genes in the clusters between
Slc22a8 and Slc22a19 of the mouse chromosome 19qA (Slc22a26, a27, a28, a29, a30), rat
anion transporters (Slc22a6, a7, a8, a9/a24, a12) and Slc22 genes in the clusters between
Slc22a8 and Slc22a19 of the rat chromosome chr1q43 (Ust4r, Ust5r, Slc22a25). The third
tree (S5 Fig) includes human SLC22A24 and the reference proteomes of all chordates
(https://www.uniprot.org/help/reference_proteome), which have sequence similarity to
human SLC22A24 with an e-value < 1x10-200. For each tree, a multiple sequence alignment
was created using MUSCLE[106], with default parameters on the CIPRES Science Gateway
[107]. Phylogenetic trees were built using a RAxML[108] installation “RAxML-HPC2 on
XSEDE” on the CIPRES Science Gateway. The tree was calculated on protein sequences
using the protein GAMMA model with the JTT substitution matrix and rapid bootstrapping
with 100 replicas. A resulting extended majority rule consensus tree was visualized using
Dendroscope 3[109]. See S1 and S2 Appendices for the amino sequences used to create the
phylogenetic tree in Fig 5A and 5B and S5 Fig.
Comparative structure modelling
Due to the lack of available crystal structures, human OCT1 (SLC22A1), OCTN1 (SLC22A4),
OAT1 (SLC22A6), and SLC22A24 were modeled using the crystal structure of the maltose-
bound human GLUT3 (SLC2A3) in the outward-open conformation at 2.6 Å as a template
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(PDB ID 4ZWC)[110]. The template was selected on the basis of the shared MFS fold assign-
ment [10], structure quality, and sequence similarity to the targets of interest (40%, 38%, 39%
sequence similarity to SLC22A1, SLC22A6, SLC22A24, respectively). The sequence alignment
was obtained by a manual refinement of gaps in the output from the PROMALS3D server
(S1A Fig) [111]. The maltose molecule from the crystal structure was treated as the BLK resi-
due type in the alignment and was copied from the template structure into a model as a rigid
body. One hundred models were generated for each protein using the “automodel” class of
MODELLER 9.16 (https://salilab.org/modeller/). The models had acceptable normalized dis-
crete optimized protein energy scores (zDOPE)[112, 113]. The top scoring models were
selected for electrostatic potential analysis with the APBS electrostatics plugin[114] within
PyMOL 2.0.3 using the AMBER force field with default settings.
Site directed mutagenesis to create SLC22A24 p.Tyr501Ter
We used the Gibson Assembly protocol from New England BioLabs (catalog no. E5510) to cre-
ate the SLC22A24 p.Tyr501Ter construct by amplifying unique segments from the SLC22A24
wild type and pCMV6-Entry vectors. The following primers were used to amplify the segment
containing SLC22A24 residues 1–500 from the SLC22A24 wild type plasmid:
forward primer GCCGCCGCGATCGCCATGGGCTTTGATGTGCTCCT
reverse primer CGGCCGCGTACGCGTGGAAATCCAGGGTAGGTGGG.
The following primers were used to amplify the segment containing the linker, tag, stop
codon, and the rest of the vector backbone from the pCMV6-Entry vector:
forward primer CTACCCTGGATTTCCACGCGTACGCGGCCGCTCGA
reverse primer CACATCAAAGCCCATGGCGATCGCGGCGGCAGATC
Each segment contains a 15 bp overhang necessary for the Gibson Assembly workflow. The
amplified segments were then assembled following the manufacturer’s protocol (https://www.
neb.com/protocols/2012/12/11/gibson-assembly-protocol-e5510).
Kidney tissue procurement
Frozen human postmortem frozen renal cortical tissues from donors aged 3 to 29 years old
were obtained from the NIH NeuroBioBank at the University of Maryland, Baltimore, MD
[115, 116]. These tissues were selected from patients, who are of self-reported African Ameri-
can descent. Tissues were procured at the time of autopsy within 48 hours after death and
were kept frozen at -80˚C for later research. Tissues were selected for having no renal abnor-
malities in pathology and primary diagnosis. Twenty kidney samples were selected for quanti-
tative proteomic analysis (see section below).
Genotype kidney tissues for SLC22A24 c.1503T>G
Genomic DNA from the 20 renal cortical tissues procured from the NIH NeuroBioBank
were isolated using Wizard genomic DNA purification kit (Promega). The following forward
(CCACAAGGGCAGAAAGTATG) and reverse primers (CAAATTATCAAAGCTGCGGG
TTA) were used to PCR the genomic region of SLC22A24 and using Sanger sequencing primer
(TAAGCCAGATATTGTTCACG) to determine the genotype for the stop-gained variant in
SLC22A24, c.1503T>G (rs11231341).
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Quantitative proteomics
Absolute quantitative proteomics was performed on the 20 renal cortical tissues. SLC22A24
and SLC22A24-551 were quantified using LC-MS/MS with Selective Reaction Monitoring
(SRM) approach by Omics Technologies, Inc. (http://www.proteomics.omicstech.com/
proteomics/srm.html, previously known as MyOmicsDx, Inc., Towson, MD, USA). The fol-
lowing are the main steps for quantitative proteomic analysis for the two transcript isoforms of
SLC22A24. The detailed material and method used for each steps are described below as well
as in our previous submitted manuscript[116]. The material and methods described below
were provided by Omics Technologies, Inc.
• Membrane protein extraction and protein preparation
• Chemicals and Reagents
• Preparation of the Chromatography Solutions
• SRM analysis
• Tuning of the Agilent 6495 Triple Quadrupole mass spectrometer
• SRM data analysis
Membrane protein extraction and protein preparation. Frozen renal cortical tissues
were processed to extract membrane proteins. Membrane protein samples were then pro-
cessed by Omics Technologies, Inc. using "Filter Assisted Sample Preparation" (FASP) method
[117]. Briefly, protein samples in 9M UREA were reduced with 5 mM TCEP at 37 ˚C for 45
min and reduced cysteine were blocked using 50 mM iodoacetmide (IAA) at 25 ˚C for 15 min.
Protein samples were then cleaned using 10 kDa Amicon Filter (UFC501096, Millipore) three
times using 9M urea and two times using MyPro-Buffer 1 (Omics Technologies, Inc.). Samples
were then proteolyzed with trypsin (V5111, Promega) for 12 hrs at 37 ˚C. The peptide solution
then was acidified by adding 1% trifluoroacetic acid (TFA) and was incubated at room temper-
ature for 15 min. A Sep-Pak light C18 cartridge (Waters Corporation) was activated by loading
5 mL 100% (vol/vol) acetonitrile and was washed by 3.5 mL 0.1% TFA solution two times.
Acidified digested peptide solution was centrifuged at 1,800 × g for 5 min, and the supernatant
was loaded into the cartridge. To desalt the peptides bound to the cartridge, 1 mL, 3 mL, and 4
mL of 0.1% TFA were used sequentially. To elute the peptides from the cartridge, 2 mL of 40%
(vol/vol) acetonitrile with 0.1% TFA was used. The eluted peptides were lyophilized overnight
and reconstituted in 37 μL MyPro-Buffer 3 (Omics Technologies, Inc.).
Chemicals and reagents. TCEP (TCEP (tris-(2-carboxyethyl) phosphine) and MMTS
(methyl methanethiosuphonate) were purchased from Thermo Scientific (Waltham, Massa-
chusetts). LysC and Trypsin proteases were purchased from Promega (Fitchburg, Wisconsin).
C18 Cartridges for sample preparation, and chromatography columns for basic reverse phase
liquid chromatographic (bRPLC) and online HPLC of Triple Quadrupole mass spectrometer
were purchased from Waters (Milford, Massachusetts). Acetonitrile was purchased from JT
Baker, and formic acid was obtained from EMD Millipore (Billerica, MA, USA). MyPro-Buffer
1, MyPro-Buffer 2 and MyPro-Buffer 3 were utilized by Omics Technologies, Inc. All other
reagents were purchased from Sigma-Aldrich (St. Louis, Missouri) unless otherwise indicated.
Preparation of the chromatography solutions. bRPLC solvent A contained 10mM
triethylammonium bicarbonate buffer (TEABC); bRPLC solvent B contained 10mM TEABC,
90% (vol/vol) acetonitrile. SRM Mass Spectrometry solvent A was comprised of water with
0.1% (vol/vol) formic acid; SRM solvent B was acetonitrile with 0.1% (vol/vol) formic Acid.
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SRM analysis. Peptide samples reconstituted in 37 μl MyPro-Buffer 3 (MyOmicsDx, Inc)
were spiked with MyPro-SRM Internal Control Mixture (MyOmicsDx, Inc) composed of a
pool of 1 femto mole heavy isotope labeled peptides covering a large hydrophobicity window
and a large M/z range (M/z 200 ~ 1300), and were subject to SRM analysis. Peptide samples
were eluted through an online Agilent 1290 HPLC system into the Jet Stream ESI source of an
Agilent 6495 Triple Quadrupole Mass spectrometer.
Tuning of the Agilent 6495 Triple Quadrupole mass spectrometer. After every preven-
tative maintenance, Agilent 6495 Triple Quadrupole mass spectrometer was tune using manu-
facturer’s tuning mixture followed by MyPro-SRM Tuning Booster (MyOmicsDx SRM tuning
mixture). Before and after every batch of SRM analysis, to ensure the stable and consistent per-
formance of the mass spectrometer throughout the entire study, MyPro-SRM Performance
Standard (MyOmicsDx), a mixture of standard peptides across a wide range of mass (M/z
100–1400) and a broad range of hydrophobicity were analyzed.
SRM data analysis. The abundance of a target peptide was represented by the total area
under the curve (AUC) of all its transitions normalized to the total AUC of all transitions
from the most nearby (sharing a similar hydrophobicity) heavy isotope-labeled peptide from
MyPro-SRM Internal Control Mixture (MyOmicsDx, Inc) spiked in before the SRM analysis.
Absolute quantification of each protein is performed through applying AQUA Peptides pur-
chased from Sigma-Aldrich. A summary of all quantification results were shown in S8 Table.
Supporting information
S1 Fig. A common splice donor variant, rs1939749, found in 3’-end of exon 1. (A) A splice
donor, rs1939749, C>T (+ DNA strand), is strongly associated with lower expression levels of
SLC22A24 in kidney tubular cells observed in two independent kidney eQTL databases, http://
susztaklab.com/eqtl and http://nephqtl.org/, p-values 3.7x10-23 (beta = 1.2, N = 121) and
1.9x10-13 (beta = 0.79, N = 166) respectively. (B) Zoom in of the SLC22A24 gene region (hg19)
flanking exon 1 and exon 2 with padding of 25 bases. This splice donor, rs1939749, C>T
(+ DNA strand), creates a premature stop.
(TIF)
S2 Fig. Steroid conjugates and bile acids uptake in HEK293 cells expressing SLC22A24 and
SLC22A8 as a function of time. (Left) Uptake of [3H]-estrone sulfate (with 1 μM unlabeled
estrone sulfate) as a function of time in cells expressing SLC22A24 and SLC22A8. The uptake
rates for estrone sulfate and two other steroid glucuronides, estradiol glucuronide and andros-
tanediol glucuronide were evaluated at 1 min. (Middle and right) Uptake of two bile acids,
[14C]-glycocholic acid (with 1 μM unlabeled glycocholic acid) and [3H]-taurocholic acid (with
1 μM unlabeled taurocholic acid) as a function of time in cells expressing SLC22A24 and
SLC22A8 (only glycocholic acid). The uptake rate for glycocholic acid and taurocholic
acid were evaluated at 1 min and 2 min respectively. Each point represents the uptake in
SLC22A24- or SLC22A8-expressing cells minus that in empty vector cells. Underlying data are
provided in S1 Data.
(TIF)
S3 Fig. Kinetic uptake of androstanediol glucuronide for SLC22A24. The uptake rate was
evaluated at 2 minutes. Each point represents the mean ± S.D. uptake in the SLC22A24-stably
transfected cells minus that in empty vector cells. Figure shows a representative plot from one
experiment. The kinetic parameters of androstanediol-3-glucuronide could not be determined
accurately due to a solubility limit of 300 μM. Using the plateau at 300 μM as an approxima-
tion, the affinity of androstanediol glucuronide was calculated as 741 ± 253 μM. The data were
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fit to a Michaelis–Menten equation. Underlying data are provided in S1 Data.
(TIF)
S4 Fig. Effect of sodium and pH on SLC22A24-mediated uptake of anion. (A) [3H]-Estrone
sulfate (with 1 μM unlabeled estrone sulfate) was incubated in the Na+ buffer (125 mM
sodium chloride, 4.8 mM potassium chloride, 1.3 mM calcium chloride, 1.3 mM magnesium
sulfate, and 5 mM HEPES, adjusted with sodium hydroxide to pH 7.4) or Na+ free buffer (125
mM choline chloride, 4.8 mM potassium chloride, 1.3 mM calcium chloride, 1.3 mM magne-
sium sulfate, and 5 mM HEPES, adjusted with TRIS-HCl to pH 7.4) for 10 min. Data shown
are from the mean ± S.D. for representative experiments of n = 2. (B) [3H]-Estrone sulfate,
[3H]-estradiol glucuronide or [3H]-taurocholic acid (with 1 μM unlabeled compound) was
incubated in the HBSS buffer adjusted to pH 5.5, 7.4 and 8.5, and the cells were incubated for
10 min. Data shown are from the mean ± S.D. for representative experiments of n = 2. Under-
lying data are provided in S1 Data.
(TIF)
S5 Fig. Phylogenetic tree indicating protein sequence relationships between human USTs
and identified mammalian orthologs. The unique and stable entry identifiers from Uni-
ProtKB (https://www.uniprot.org/) are shown in parentheses. Red arrow points to the human
SLC22A24.
(TIF)
S6 Fig. Plasma membrane expressions of SLC22A24-GFP tagged from five different spe-
cies. GFP fusion constructs were generated for the human, rabbit, horse, and mouse lemur
SLC22A24 and the rat Slc22a9/Slc22a24. HEK293 cells were transiently transfected with the
GFP fusion constructs. The cells were visualized by confocal microscopy to determine whether
the GFP fused protein is expressed on plasma membrane.
(TIF)
S7 Fig. Plasma membrane expression, transport uptake, and predicted structure of
human SLC22A24 or SLC22A24-322. (A) GFP fusion constructs were generated for human
SLC22A24 and SLC22A24-322. HEK293T cells were transient transfected with the GFP fusion
constructs. The cells were visualized by confocal microscopy to determine whether the GFP
fused protein is expressed on plasma membrane. (B) The uptake experiments of various anions
were performed for 10 minutes in triplicate wells using trace amount of the radiolabeled com-
pound. Experiments were repeated once. Underlying data are provided in S1 Data. (C) A com-
parative structure model of the human SLC22A24 with 12 transmembrane helices (white and
red). SLC22A24-322 is predicted to consist of transmembrane helices 1–6 (white), but missing
transmembrane helices 7–12 (red).
(TIF)
S8 Fig. Schematic figure showing the amino acid differences between SLC22A24 and its
isoform, SLC22A24-551. (A) Zoom in of the SLC22A24 gene region (reverse direction)
between exon 9 and exon 10 along with padding of 10 bases using UCSC browser. The allele
“CT” from position 1 and position 2 resulted in formation of two different isoforms (splice
variants) of SLC22A24. (B) Zoom in of the SLC22A24 amino acids between exon 9 and
exon 10. Arrows show the differences in amino acid positions 533 and 534, which lead to
SLC22A24-551 and SLC22A24 proteins.
(TIF)
S9 Fig. Protein and transcript levels of SLC22A24 quantified by western blots and qRT-
PCR. (A) Western blot of cells expressing empty vector, SLC22A24, SLC22A24 p.Tyr501Ter,
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and SLC22A24-322. The latter two were not expressed on the plasma membrane despite
detectable mRNA levels. (B) Transcript levels of mRNA measured using Taqman assay in
HEK293 Flp-In cells transiently expressing empty vector, SLC22A24, SLC22A24-322 and
SLC22A24 p.Tyr501Ter. Underlying data are provided in S1 Data.
(TIF)
S10 Fig. Alignment of SLC22A24 and SLC22A24-551. The peptides of interest and their cor-
responding fragments used to quantify the protein levels of SLC22A24 and SLC22A24-551 are
outlined in black. Peptide 1 corresponds to the SLC22A24 and SLC22A24-551 proteins. Pep-
tides 2 and 3 correspond to SLC22A24 and SLC22A24-551, respectively.
(TIF)
S1 Table. Metabolites that are significantly associated with SNPs within SLC22A24 locus.
(XLSX)
S2 Table. Association of SLC22A10 and SLC22A25 missense and nonsense variants with
two steroid conjugates.
(XLSX)
S3 Table. Results from metabolomic study using Metabolon Inc. technology.
(XLSX)
S4 Table. Experimental data of uptake in members of the SLC22 family used as positive
controls.
(XLSX)
S5 Table. Kinetic parameters of steroid conjugates and bile acids uptake by SLC22A24.
(DOCX)
S6 Table. List of metabolites or prescription drugs used in the inhibition studies.
(XLSX)
S7 Table. Source of cDNA.
(DOCX)
S8 Table. Results from SRM analysis.
(XLSX)
S9 Table. Primers and PCR conditions used in this study.
(DOCX)
S10 Table. Transcript levels of 22 genes in SLC22 family in kidney samples.
(XLSX)
S11 Table. List of renal transporters in the solute carrier (SLC) superfamily that are known
to have apical membrane localization.
(DOCX)
S12 Table. Phenome-wide association results of two SNPs in SLC22A24.
(XLSX)
S13 Table. Association results of variants in SLC22A24 locus with acne/acne vulgaris
extracted from UKBiobank.
(XLSX)
S1 Appendix. FASTA file containing amino acid sequences of solute carrier family 22
(human, mouse and rat). These sequences in FASTA format is used to create phylogenetic
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tree in Fig 5A.
(TXT)
S2 Appendix. FASTA file containing amino acid sequences of anion transporters of the
solute carrier family 22 (human, primates, mouse, rat and other species). These sequences
in FASTA format is used to create phylogenetic tree in Fig 5B and S5 Fig.
(TXT)
S1 Data. Contains underlying data for figures.
(XLSX)
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